SCHEMBL4885795

SCHEMBL4885795

CC(=O)SCC(=O)c1ccc(CSCCc2ccccn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 6/20 0.47
HDAC4 P56524 6/20 0.47
HDAC1 Q13547 6/20 0.47
HDAC7 Q8WUI4 6/20 0.47
HDAC2 Q92769 6/20 0.47
HDAC10 Q969S8 6/20 0.47
HDAC11 Q96DB2 6/20 0.47
HDAC8 Q9BY41 6/20 0.47
HDAC6 Q9UBN7 6/20 0.47
HDAC9 Q9UKV0 6/20 0.47
HDAC5 Q9UQL6 6/20 0.47
ALDH1A1 P00352 5/20 0.47
CYP1A2 P05177 2/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886865 0.84 HDAC3 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL177882 0.77 ALDH1A1 (0.53) ALDH1A1CYP1A2TSHRHTTSMN1; SMN2
SCHEMBL29993219 0.77 ALDH1A1 (0.53) ALDH1A1CYP1A2TSHRHTTSMN1; SMN2
SCHEMBL16346393 0.75 CYP1A2 (0.61) ALDH1A1CYP1A2HTTSMN1; SMN2NPC1
SCHEMBL4880410 0.74 LMNA (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4887379 0.74 SMN1; SMN2 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL4878351 0.73 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL23120091 0.72 CYP1A2 (0.57) ALDH1A1CYP1A2HTTSMN1; SMN2NPC1
SCHEMBL29595506 0.72 CYP1A2 (0.57) ALDH1A1CYP1A2HTTSMN1; SMN2NPC1
SCHEMBL5017194 0.71 CYP1A2 (0.53) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease KALYPSYS, INC. (US) 2008-08-14 US disclosed
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease KALYPSYS, INC. (US) 2008-08-14 US disclosed
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease KALYPSYS, INC. (US) 2008-08-14 US disclosed
EP-1819669-A2 NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE Kalypsys, Inc. (US) 2007-08-22 EP disclosed
WO-2006063294-A2 NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2006-06-15 WO disclosed
WO-2006063294-A2 NOVEL INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194681-A1 Novel Inhibitors of Histone Deacetylase for the Treatment of Disease HDAC1, HDAC10, HDAC6 HDAC3 11/4885HDAC4 8/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.